期刊文献+

Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease 被引量:7

Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
下载PDF
导出
摘要 Non-alcoholic fatty liver disease(NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor(FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第37期13493-13500,共8页 世界胃肠病学杂志(英文版)
基金 Supported by National Nature Science Foundation of China,No.81273727 and No.81302927 Innovation Program of Shanghai Municipal Education Commission,No.14YZ054
关键词 Farnesoid X RECEPTOR Non-alcoholic FATTY liver DIS Farnesoid X receptor Non-alcoholic fatty liver disease Mechanism Therapy Lipid metabolism
  • 相关文献

参考文献12

  • 1辛小敏,钟慕晓,张珊珊,彭瑶,朱薇,张亚历.胆汁酸核受体激动剂对脂联素及其受体的影响[J].南方医科大学学报,2014,34(1):109-112. 被引量:3
  • 2Zhenghui Gordon Jiang,Simon C. Robson,Zemin Yao.Lipoprotein metabolism in nonalcoholic fatty liver disease[J].The Journal of Biomedical Research,2013,27(1):1-13. 被引量:8
  • 3Marion J. Pollheimer,Peter Fickert,Bruno Stieger.Chronic cholestatic liver diseases: Clues from histopathology for pathogenesis[J].Molecular Aspects of Medicine.2014
  • 4Xian-Feng Lin,Ke-Qing Shi,Jie You,Wen-Yue Liu,Ying-Wan Luo,Fa-Ling Wu,Yong-Ping Chen,Danny Ka-Ho Wong,Man-Fung Yuen,Ming-Hua Zheng.Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study[J].Molecular Biology Reports.2014(5)
  • 5R. Kwok,Y.‐K. Tse,G. L.‐H. Wong,Y. Ha,A. U. Lee,M. C. Ngu,H. L.‐Y. Chan,V. W.‐S. Wong.Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments[J].Aliment Pharmacol Ther.2014(3)
  • 6Xinwei Li,Wentao Yang,Chong Xiao,Shixin Fu,Qinghua Deng,Hongyan Ding,Zhe Wang,Guowen Liu,Xiaobing Li.SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes[J].Journal of Steroid Biochemistry and Molecular Biology.2014
  • 7Xuelian Xiong,Xiaolin Wang,Yan Lu,E. Wang,Zhijian Zhang,Jian Yang,Huijie Zhang,Xiaoying Li.Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice[J].Journal of Hepatology.2013
  • 8Hamdy Abd El Azeem,El-Shazly Abdul Khalek,Hazem El-Akabawy,Hussein Naeim,Hammouda Abdul Khalik,Abdul Aziz Alfifi.Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events[J].Journal of the Saudi Heart Association.2013(4)
  • 9Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi I. Sciacca,Paul Clopton,Erin Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro.Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[J].Gastroenterology.2013
  • 10Yongjie Ma,Yixian Huang,Linna Yan,Mingming Gao,Dexi Liu.Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance[J].Pharmaceutical Research.2013(5)

二级参考文献11

  • 1Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: key regulator of whole-body energy metabolism[J]. Trends Endocrinol Metab, 2011, 22(11): 458-66.
  • 2Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (faJfa) obese rats[J]. J Lipid Res, 2010, 51(4): 771-84.
  • 3Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity 1999 [J]. Biochem Biophys Res Commun, 2012, 425(3): 560-4.
  • 4Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease[J], Diabetes Obes Metab, 2010, 12(5): 365-83.
  • 5Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects [J]. Nature, 2003, 423 (6941): 762-9.
  • 6Nazal L, Riquelme A, Sol/s N, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients [J]. Obes Surg, 2010, 20(10): 1400-7.
  • 7Akiko S, Takamura T, Matsuzawa N, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line[J]. Metabolism, 2007, 56(11): 1478-85.
  • 8Schmidt MV, Brtine B, yon Knethen A. The nuclear hormone receptor PPAR7 as a therapeutic target in major diseases [J]. Sci World J, 2010, 10: 2181-97.
  • 9Zhang F, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-'/ cross-regulation of signaling events implicated in liver fibrogenesis[J]. Cell Signal, 2012, 24(3): 596-605.
  • 10Rizzo G, Disante M, Mencarelli A, et al. The famesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo[J]. Mol Pharmacol, 2006, 70(4): 1164-73.

共引文献21

同被引文献39

引证文献7

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部